pertuzumab sold brand name perjeta monoclonal antibody used combination trastuzumab docetaxel treatment metastatic breast cancer also used combination neoadjuvant early breast side effects half people taking include diarrhea hair loss loss neutrophils experience loss red blood cells hypersensitivity allergic reaction infusion reactions decreased appetite insomnia distortions sense taste inflammation mouth lips constipation rashes nail disease muscle women pregnant planning getting pregnant take studied people certain heart conditions used caution people used unknown pertuzumab interacts firstinclass kind drug called dimerization inhibitor inhibits dimerization receptors prevents signalling ways promote cell growth discovered developed genentech first approved pertuzumab administered intravenous infusion combination trastuzumab docetaxel first line treatment metastatic breast also used combination neoadjuvant given reduce size tumor prior surgery radiation early breast cancer use shown increase pertuzumab studied people left ventricular ejection fraction value normal prior history congestive heart failure conditions could impair left ventricular function like uncontrolled hypertension recent heart attacks serious cardiac caution used combining pertuzumab also safety data available use pertuzumab combination women childbearing age use contraception taking pertuzumab may damage fetus pregnant women may secreted breast clinical trials threeagent combination therapy metastatic breast cancer adverse effects occurring half people taking included diarrhea hair loss loss neutrophils people experienced loss neutrophils fever loss docetaxel dropped people common adverse effects diarrhea upper respiratory tract infection rash headache fatigue swelling nasal passages throat often due catching common cold weakness itchiness joint pain nausea pain extremity back pain cough clinical trials neoadjuvant use combination people hair loss loss uses people additionally experienced loss red blood cells hypersensitivity allergic reaction infusion reactions decreased appetite insomnia distortions sense taste inflammation mouth lips constipation rashes nail disease muscle metabolism pertuzumab directly studied general antibodies cleared principally catabolism median clearance pertuzumab litersday median halflife extracellular receptor tyrosine kinase activated sets signal transduction several pathways stimulate cell proliferation cell growth overexpressed cause uncontrollable growth positive breast cancer caused gene amplification results overexpression approximately breast cancer like many receptors normally combines another protein order function process called dimerization bind second receptor acting homodimer heterodimerize different receptor family potent dimer activating signalling pathways epitope pertuzumab domain binds pertuzumab prevents dimer forming blocks signalling trastuzumab another monoclonal antibody epitope domain binds another two mabs together prevent pertuzumab immunoglobulin variable region human protein humanmouse monoclonal heavy chain disulfide bound humanmouse monoclonal manufactured recombinantly cho monoclonal antibody appears first published scientists year f hoffmannla roche ag acquired majority stake genentech understood prevented dimerizing receptors begun phase trials aiming broad range cancers ones overexpressing first known dimerization genentech presented poor results phase ii trials pertuzumab single agent prostate breast ovarian cancers said intended continue developing combination drugs ovarian genentech dropped trade name march roche acquired results published cleopatra trial randomized placebocontrolled phase iii trial pertuzumab combination trastuzumab docetaxel metastatic breast pertuzumab received us fda approval treatment metastatic breast cancer later results phase ii trial neoadjuvant setting neosphere published results phase ii cardiac safety study population tryphaena published fda approved neoadjuvant indication pertuzumab approved medical use european union us cycle threedrug combination given every three weeks costs around including ancillary care uk nice evaluation made preliminary finding drug combination cost effective nice rejected drug neoadjuvant setting may primarily unknown drug combination provided survival decision subsequently reversed six months later pertuzumab became first new breast cancer drug approved nice routine nhs funding almost decade roche pledged provide drug nhs undisclosed discount patients neoadjuvant setting share financial httpsenwikipediaorgwikipertuzumab